Cempra Inc Receives a Hold from Jefferies

By Austin Angelo

In a report issued on September 12, Eun Yang from Jefferies reiterated a Hold rating on Cempra Inc (NASDAQ: CEMP), with a price target of $3. The company’s shares opened today at $3.10, close to its 52-week low of $2.55.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 5.8% and a 52.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, DBV Technologies SA – American, and Iovance Biotherapeutics Inc.

Cempra Inc has an analyst consensus of Hold, with a price target consensus of $3.67.

Based on Cempra Inc’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $860K and GAAP net loss of $12.27 million. In comparison, last year the company earned revenue of $3.42 million and had a GAAP net loss of $24.81 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cempra, Inc. engages as a clinical-stage pharmaceutical company, which focuses on the development of antibacterials to meet critical medical needs. Its products include; Solithromycin and Taksta. The company was founded by Prabhavathi B. Fernandes on November 18, 2005 and is headquartered in Chapel Hill, NC.